{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:37:14Z","timestamp":1786361834855,"version":"build-2736575974"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cpet.2026.06.015","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:23:10Z","timestamp":1786360990000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fluorodeoxyglucose PET\/Computed Tomography in Multimodality and Theranostic Workflows"],"prefix":"10.1016","author":[{"given":"Yogita","family":"Khandelwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Bishnoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cpet.2026.06.015_bib1","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2967\/jnumed.116.178343","article-title":"Nuclear medicine in cancer theranostics: beyond the target","volume":"57","author":"Ta\u00efeb","year":"2016","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.3645","article-title":"THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy - the bad berka experience","volume":"2","author":"Baum","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.cpet.2026.06.015_bib3","doi-asserted-by":"crossref","unstructured":"Baum RP, R\u04e7sch F, Boschi S, et al. Theranostics, Gallium-68 and Other Radionuclides \u2013 A Pathway to Personalized Diagnosis and Treatment. Vol 194. 2013. doi:10.1007\/978-3-642-27994-2.","DOI":"10.1007\/978-3-642-27994-2"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cpet.2026.06.015_bib5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"10276","key":"10.1016\/j.cpet.2026.06.015_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"10459","key":"10.1016\/j.cpet.2026.06.015_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cpet.2026.06.015_bib8","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.cpet.2026.06.015_bib9","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.cpet.2026.06.015_bib10","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","article-title":"Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE","volume":"37","author":"Virgolini","year":"2010","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.cpet.2026.06.015_bib11","first-page":"333","article-title":"Molecular imaging in oncology: current impact and future directions","volume":"72","author":"Rowe","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin Receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.cpet.2026.06.015_bib13","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","article-title":"Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC","volume":"52","author":"Telli","year":"2025","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"12","key":"10.1016\/j.cpet.2026.06.015_bib14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","article-title":"Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging","volume":"44","author":"Sheikhbahaei","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib16","first-page":"885","article-title":"Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0","volume":"47","author":"Delbeke","year":"2006","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"10.1016\/j.cpet.2026.06.015_bib17","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.2967\/jnumed.108.053751","article-title":"Molecualr imaging of cancer: from molecules to humans. Introduction","volume":"49","author":"Gambhir","year":"2008","journal-title":"J Nucl Med"},{"issue":"27","key":"10.1016\/j.cpet.2026.06.015_bib18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00259-022-05961-z","article-title":"Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET\/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy","volume":"50","author":"Alberts","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"8","key":"10.1016\/j.cpet.2026.06.015_bib20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/cancers13081813","article-title":"Clinical utility of 18F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis","volume":"13","author":"Alevroudis","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","article-title":"Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-\/[18F]F-PSMA-11\/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET\/CT: a pilot study","volume":"52","author":"Pabst","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","article-title":"SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors","volume":"17","author":"Kratochwil","year":"2015","journal-title":"Mol Imag Biol"},{"issue":"11","key":"10.1016\/j.cpet.2026.06.015_bib23","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1007\/s00259-016-3395-4","article-title":"Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours","volume":"43","author":"Virgolini","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.cpet.2026.06.015_bib25","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","article-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG","volume":"112","author":"Kayani","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2967\/jnumed.116.178095","article-title":"Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET\/CT on clinical management in patients with neuroendocrine tumors","volume":"58","author":"Panagiotidis","year":"2017","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2026.06.015_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2967\/jnumed.114.137166","article-title":"Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s00259-017-3821-2","article-title":"Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis","volume":"45","author":"Thang","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1677\/ERC-10-0233","article-title":"Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?","volume":"18","author":"Deandreis","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.cpet.2026.06.015_bib30","doi-asserted-by":"crossref","first-page":"R627","DOI":"10.1530\/ERC-19-0165","article-title":"Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups","volume":"26","author":"Ta\u00efeb","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib31","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cpet.2026.06.015_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejso.2010.01.001","article-title":"Dual PET\/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging","volume":"36","author":"Marzola","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2026.06.015_bib33","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2967\/jnumed.108.060467","article-title":"123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma","volume":"50","author":"Sharp","year":"2009","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2026.06.015_bib34","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.121.262808","article-title":"Pitfalls and common findings in 68Ga-FAPI PET: a pictorial analysis","volume":"63","author":"Kessler","year":"2022","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular Non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.cpet.2026.06.015_bib36","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2026.06.015_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eanmj.2025.100006","article-title":"[18F]FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 3.0","volume":"1","author":"Boellaard","year":"2025","journal-title":"The EANM Journal"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2026.06.015_bib38","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2026.06.015_bib42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.cpet.2026.06.015_bib43","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2026.06.015_bib44","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00259-014-2788-5","article-title":"Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)","volume":"41","author":"Kong","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib45","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/RLU.0b013e31827a216b","article-title":"Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?","volume":"39","author":"Naswa","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The impact of 68Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom","volume":"57","author":"Skoura","year":"2016","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1016\/j.cpet.2026.06.015_bib47","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1007\/s00259-025-07351-7","article-title":"Novel framework for response evaluation criteria in grade 1\/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial","volume":"52","author":"Satapathy","year":"2025","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11307-018-1252-5","article-title":"Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy","volume":"21","author":"Werner","year":"2019","journal-title":"Mol Imag Biol"},{"key":"10.1016\/j.cpet.2026.06.015_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1607227","article-title":"Diagnostic value of dual-tracer PET\/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review","volume":"12","author":"Iacovitti","year":"2025","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib51","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","article-title":"68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making","volume":"45","author":"Grubm\u00fcller","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"8","key":"10.1016\/j.cpet.2026.06.015_bib53","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.cpet.2026.06.015_bib54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.1946.02870190005002","article-title":"Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism","volume":"131","author":"Hertz","year":"1946","journal-title":"J Am Med Assoc"},{"issue":"8","key":"10.1016\/j.cpet.2026.06.015_bib55","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1089\/thy.2012.0081","article-title":"Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels","volume":"22","author":"Leboulleux","year":"2012","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib57","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0067","article-title":"2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management","volume":"12","author":"Durante","year":"2023","journal-title":"Eur Thyroid J"},{"issue":"10","key":"10.1016\/j.cpet.2026.06.015_bib58","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1089\/thy.2023.0264","volume":"33","author":"Bang","year":"2023","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.cpet.2026.06.015_bib59","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/RLU.0b013e31825b2057","volume":"37","author":"Vural","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib60","doi-asserted-by":"crossref","first-page":"183","DOI":"10.21873\/anticanres.16148","article-title":"Utility of FDG PET at the initial radioiodine therapy in differentiated thyroid cancer","volume":"43","author":"Matsuo","year":"2023","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib61","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/cancers15030923","article-title":"Management of recurrent well-differentiated thyroid carcinoma in the neck: a comprehensive review","volume":"15","author":"Cavalheiro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpet.2026.06.015_bib62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cpet.2026.06.015_bib63","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/375231","article-title":"Correlation between calcitonin levels and [18F]FDG-PET\/CT in the detection of recurrence in patients with sporadic and hereditary medullary thyroid cancer","volume":"2012","author":"Skoura","year":"2012","journal-title":"ISRN Endocrinol"},{"issue":"8","key":"10.1016\/j.cpet.2026.06.015_bib64","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4158\/EP171806.OR","article-title":"The combined use of calcitonin doubling time and 18F-FDG pet\/ct IMPROVES prognostic values in medullary thyroid carcinoma: the clinical utility of 18F-FDG PET\/CT","volume":"23","author":"Yang","year":"2017","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2967\/jnumed.117.199778","article-title":"Predictive value of 18F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib","volume":"59","author":"Werner","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib66","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3803\/EnM.2021.1082","article-title":"Current guidelines for management of medullary thyroid carcinoma","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.cpet.2026.06.015_bib67","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2265.2008.03257.x","article-title":"The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas","volume":"69","author":"Ta\u00efeb","year":"2008","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib68","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00259-013-2598-1","article-title":"Diagnostic accuracy of (68)Ga-DOTANOC PET\/CT imaging in pheochromocytoma","volume":"41","author":"Sharma","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"10.1016\/j.cpet.2026.06.015_bib69","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2026.06.015_bib70","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00259-018-4070-8","article-title":"Guidelines on nuclear medicine imaging in neuroblastoma","volume":"45","author":"Bar-Sever","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.cpet.2026.06.015_bib71","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/MNM.0000000000000347","article-title":"Diagnostic value of 18F-FDG PET\/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy","volume":"36","author":"Dhull","year":"2015","journal-title":"Nucl Med Commun"},{"issue":"9","key":"10.1016\/j.cpet.2026.06.015_bib72","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.21037\/qims-22-1420","article-title":"The application of 18F-FDG PET\/CT imaging for human hepatocellular carcinoma: a narrative review","volume":"13","author":"Yao","year":"2023","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2214\/AJR.21.26485","article-title":"Utility of early posttreatment PET\/CT evaluation using FDG or 18F-FCH to predict response to 90Y radioembolization in patients with hepatocellular carcinoma","volume":"218","author":"Reizine","year":"2022","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.cpet.2026.06.015_bib75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fonc.2013.00177","article-title":"Radioimmunotherapy of B-Cell non-hodgkin\u2019s lymphoma","volume":"3","author":"Bodet-Milin","year":"2013","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2026.06.015_bib76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"10.1016\/j.cpet.2026.06.015_bib77","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/1450-1147.150509","article-title":"Radiosynovectomy in the therapeutic management of arthritis","volume":"14","author":"Knut","year":"2015","journal-title":"World J Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib79","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00259-021-05541-7","article-title":"The EANM guideline for radiosynoviorthesis","volume":"49","author":"Kampen","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"8","key":"10.1016\/j.cpet.2026.06.015_bib80","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.40860","article-title":"Development and validation of an 18 F-Fluorodeoxyglucose-Positron emission tomography with computed tomography-based tool for the evaluation of joint counts and disease activity in patients with rheumatoid arthritis","volume":"71","author":"Lee","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib81","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy : report on the EANM symposium on immune modulation and recent review of the literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib82","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.06.015_bib83","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","article-title":"Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST","volume":"9","author":"Goldfarb","year":"2019","journal-title":"EJNMMI Res"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib84","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2967\/jnumed.124.268903","article-title":"Dosimetry of [177Lu]Lu-DOTATATE in patients with advanced midgut neuroendocrine tumors: results from a substudy of the phase III NETTER-1 trial","volume":"66","author":"Bodei","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41747-022-00282-0","article-title":"Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics","volume":"6","author":"Liberini","year":"2022","journal-title":"Eur Radiol Exp"},{"issue":"2","key":"10.1016\/j.cpet.2026.06.015_bib86","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2019191114","article-title":"18F-FDG PET\/CT uptake classification in lymphoma and lung cancer by using deep convolutional neural networks","volume":"294","author":"Sibille","year":"2020","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2967\/jnumed.116.184028","article-title":"Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care","volume":"59","author":"Cherry","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib88","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2967\/jnumed.119.226498","article-title":"First human imaging studies with the EXPLORER total-body PET scanner","volume":"60","author":"Badawi","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.06.015_bib89","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41181-019-0069-0","article-title":"Targeting of activated fibroblasts for imaging and therapy","volume":"4","author":"Lindner","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib90","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2026.06.015_bib91","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based Theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib92","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-In-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2026.06.015_bib93","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","article-title":"The role of 68Ga-FAPI PET\/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience","volume":"61","author":"Koerber","year":"2020","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2026.06.015_bib94","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/MNM.0000000000001607","article-title":"Comparison of 18 F-FDG PET\/CT and 68 Ga-FAPI-04 PET\/CT in patients with non-small cell lung cancer","volume":"43","author":"Can","year":"2022","journal-title":"Nucl Med Commun"},{"issue":"6","key":"10.1016\/j.cpet.2026.06.015_bib95","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12149-008-0149-9","article-title":"The influence of I-131 therapy on FDG uptake in differentiated thyroid cancer","volume":"22","author":"Hung","year":"2008","journal-title":"Ann Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2026.06.015_bib96","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/RLU.0b013e318125037a","article-title":"F-18 FDG PET\/CT in the management of thyroid cancer","volume":"32","author":"Iagaru","year":"2007","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2026.06.015_bib97","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s002689900439","article-title":"Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?","volume":"22","author":"Pasquali","year":"1998","journal-title":"World J Surg"},{"issue":"12","key":"10.1016\/j.cpet.2026.06.015_bib98","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1007\/s00261-022-03516-2","article-title":"PET\/CT and PET\/MRI in neuroendocrine neoplasms","volume":"47","author":"Rajamohan","year":"2022","journal-title":"Abdom Radiol"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib99","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","article-title":"PET\/MRI in prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Evangelista","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2026.06.015_bib100","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3390\/ijms21031029","article-title":"The added value of diagnostic and theranostic PET imaging for the treatment of CNS tumors","volume":"21","author":"Pruis","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:23:22Z","timestamp":1786361002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859826000684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":99,"alternative-id":["S1556859826000684"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2026.06.015","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluorodeoxyglucose PET\/Computed Tomography in Multimodality and Theranostic Workflows","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2026.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}